Search

Your search keyword '"REDUCING LIPIDS"' showing total 18 results

Search Constraints

Start Over You searched for: Descriptor "REDUCING LIPIDS" Remove constraint Descriptor: "REDUCING LIPIDS"
18 results on '"REDUCING LIPIDS"'

Search Results

1. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease

2. Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals

3. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes

4. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial

5. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

6. Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and Coronary Artery Disease

7. 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

8. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

9. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the Treating to New Targets (TNT) trial

10. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment

11. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

12. Cognitive Function in a Randomized Trial of Evolocumab

13. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study

14. Inclisiran in patients with high CV risk and elevated LDL-cholesterol

15. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

16. Evolocumab and clinical outcomes in patients with cardiovascular disease

17. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial

18. Determining When to Add Nonstatin Therapy: A Quantitative Approach

Catalog

Books, media, physical & digital resources